Odontogenic infection in the immunocompromised/diabetic
High-risk dental sepsis · Dental & Oral
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Dental and oral infections in diabetic, neutropenic, immunosuppressed or steroid-dependent patients can progress rapidly with blunted clinical signs, atypical organisms and a markedly higher risk of deep space spread, necrotising infection and sepsis. A low threshold for admission and imaging is essential.
Red flags
- Rapid spread / disproportionate systemic illness
- DKA or uncontrolled hyperglycaemia with sepsis
- Black nasal/palatal eschar (mucormycosis)
- Neutropenic sepsis
- Airway compromise
Assessment
Differential diagnosis
- Simple odontogenic abscess
- Deep neck space infection
- Necrotising soft-tissue infection (cervicofacial)
- Invasive fungal infection (mucormycosis) in diabetics
- Neutropenic oral ulceration/mucositis
- Ludwig's angina
Investigations
- Assess immune status (diabetes/HbA1c, neutrophil count, immunosuppressants, HIV)
- Full sepsis screen: FBC, CRP, U&E, glucose/ketones, lactate, blood cultures
- Capillary/venous glucose and ketones (DKA risk with sepsis)
- CT neck with contrast with a low threshold for deep spread
- Assess airway, trismus, floor of mouth
- Consider fungal involvement (nasal eschar) in diabetics
Management
- Resuscitate per sepsis pathway; monitor for DKA/HHS in diabetics
- Low threshold for IV broad-spectrum antibiotics and early imaging
- Optimise glycaemic control; treat DKA if present
- Early surgical source control — drainage and/or extraction without delay
- Admit with close observation; many need HDU-level monitoring
- Involve OMFS early; consider microbiology/infectious diseases for atypical organisms
- Exclude invasive fungal disease in poorly controlled diabetics (urgent ENT/OMFS and antifungals)
- Review/optimise immunosuppression with the relevant specialty
Drugs & doses
Co-amoxiclav — 1.2 g IV TDS — empirical broad cover
Piperacillin-tazobactam — 4.5 g IV QDS — if severe/neutropenic sepsis
Metronidazole — 500 mg IV TDS — anaerobic cover
Clindamycin — 600 mg IV QDS — penicillin allergy
Liposomal amphotericin B — 5 mg/kg IV daily — if mucormycosis suspected (specialist)
Disposition
Admit for IV antibiotics, early surgical source control and glycaemic optimisation; HDU/ICU and specialist input (OMFS, microbiology, ID) for severe or atypical infection.
Complications & pitfalls
- Rapidly progressive deep neck infection / necrotising fasciitis
- Mucormycosis (diabetics)
- Septic shock and multi-organ failure
- DKA/HHS
- Delayed healing
Exam pearls
- Clinical signs are blunted in the immunocompromised — treat and image earlier than you would otherwise
- Sepsis can precipitate DKA, and DKA worsens sepsis — check ketones
- A diabetic with facial infection and a necrotic nasal/palatal lesion needs urgent exclusion of mucormycosis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.